Drugs that contain Degarelix Acetate
1. List of Firmagon drug patents
FIRMAGON's oppositions filed in EPO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9579359 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US10973870 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US10729739 | FERRING | Methods of treating prostate cancer with GnRH antagonist |
Feb, 2029
(5 years from now) | |
| US9415085 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(9 years from now) | |
| US10695398 | FERRING | Method of treating prostate cancer with GnRH antagonist |
Apr, 2032
(9 years from now) | |
Market Authorisation Date: 24 December, 2008
Treatment: Treatment of advanced prostate cancer with a reduced likelihood of causing a gonadotrophin releasing hormone agonist side-effect; Method of treating prostate cancer
Dosage: POWDER;SUBCUTANEOUS
How can I launch a generic of FIRMAGON before it's patent expiration?
More Information on Dosage
FIRMAGON family patents
17
United States
12
Japan
8
Korea, Republic of
7
European Union
5
Hong Kong
4
China
4
EA
4
New Zealand
3
Denmark
3
Slovenia
3
Croatia
3
Portugal
3
Cyprus
3
Spain
3
Poland
2
Israel
2
IB
2
Mexico
2
Australia
2
Russia
2
Brazil
2
Taiwan, Province of China
2
Canada
1
South Africa
1
Jordan
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic